Garcinol as an Epigenetic Modulator: Mechanisms of Anti-Cancer Activity and Therapeutic Potential
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262210917 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Geethika Pochana und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology and Cancer Research, Tuskegee University, 1200 W Montgomery Rd, Tuskegee, AL 36088, USA. Hauptthemen laut MEDLINE: Terpenes, Epigenesis, Genetic, Neoplasms, Antineoplastic Agents. Die Arbeit nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIMHD NIH HHS, NHGRI NIH HHS, National Institute on Minority Health and Health Disparities.
Abstract (Originalsprache)
The limitations of conventional cancer therapies, including toxicity and resistance, underscore the need for safer and more versatile alternatives that can either complement or substitute existing regimens. Garcinol, a polyisoprenylated benzophenone derived primarily from the rind and leaves of Garcinia indica and Garcinia cambogia, has drawn significant interest in recent decades. Although traditionally used to relieve inflammatory disorders, its biomedical relevance expanded considerably after reports in the late 20th century demonstrated antimicrobial and subsequently anti-cancer properties. A growing body of cell-based research, supported by a smaller set of animal experiments, now suggests that garcinol acts as a potent epigenetic modulator. Its activities include inhibition of histone acetyltransferases (HATs), a groundbreaking research followed by regulation of oncogenic microRNAs, and modulation of signaling pathways critical to tumor progression. This review integrates current findings on garcinol’s dual role as a HAT inhibitor and regulator of oncogenic networks with updates on in vitro and in vivo studies with a more focused approach on in vivo animal models, highlighting its potential as an emerging therapeutic against malignancies and inflammatory diseases. Nonetheless, translation into clinical settings remains premature, as robust in vivo evidence is sparse and human trials are lacking. Moving forward, systematic investigations are required to clarify safety profiles, establish effective dosing strategies, and evaluate its efficacy across different cancer types.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology and Cancer Research, Tuskegee University, 1200 W Montgomery Rd, Tuskegee, AL 36088, USA.
ORCID-Profile: Balasubramanyam Karanam
Förderung
- NIMHD NIH HHS
- NHGRI NIH HHS
- National Institute on Minority Health and Health Disparities
- National Human Genome Research Institute
Zitieren
APA
Pochana, G., Karanam, T. S., Mack, S., & Karanam, B. (2025). Garcinol as an Epigenetic Modulator: Mechanisms of Anti-Cancer Activity and Therapeutic Potential. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262210917
Vancouver
Pochana G, Karanam TS, Mack S, Karanam B. Garcinol as an Epigenetic Modulator: Mechanisms of Anti-Cancer Activity and Therapeutic Potential. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262210917
BibTeX
@article{Pochana2025,
author = {Pochana, Geethika and Karanam, Tejaswini Sai and Mack, Shacoya and Karanam, Balasubramanyam},
title = {Garcinol as an Epigenetic Modulator: Mechanisms of Anti-Cancer Activity and Therapeutic Potential},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262210917}
}
EUVIMED